A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 主要终点
- Genetic profiling results
研究概览
简要总结
The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.
详细描述
Prostate cancer is the commonest malignancy and the second leading cause of tumor-related death among males worldwide. Though patients with early stage prostate cancer can obtain satisfactory therapeutic efficacy from radical prostatectomy or radiotherapy, the prognosis of men with metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC), is still poor. Recent years have witnessed the rapid development of the high-throughput technologies, including genomic, transcriptomic, epigenomic and proteomic methods. These techniques are promising in uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.
In the current prospective study, the investigators plan to perform multi-omics technologies in patients with mPCa, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Pathological confirmation of prostate cancer
- •Age: ≥40 years old
- •Bone or visceral metastatic disease confirmed by image examination.
- •Written informed consent
排除标准
- •Patients harbouring other types of cancer besides prostate cancer
结局指标
主要结局
Genetic profiling results
时间窗: From baseline (initial diagnosis of PCa), until study completion (48 months)
Mutation identified via whole-genome sequencing will be recored.
Transcriptional profiling results
时间窗: From baseline (initial diagnosis of PCa), until study completion (48 months)
Determining the transcriptomic information of metastatic prostate cancer by performing whole transcriptome sequencing
Epigenomic profiling results
时间窗: From baseline (initial diagnosis of PCa), until study completion (48 months)
Determining the epigenomic status of specific genes by performing DNA-methylation sequencing
次要结局
- Protein expression results(From baseline (initial diagnosis of PCa), until study completion (48 months))
研究者
Hao Zeng
Vice director of the department of urology
West China Hospital